Long-Term Endoscopic Management of Recurrent High-Grade Dysplasia and Intramucosal Carcinoma in an Inoperable Barrett Patient Authors: Mohamed Alharami, Ahmad Anbar, Ziad Suleiman, Mohammad Alali, Hadi Hemaidan Published: 2026 ABSTRACT ABSTRACTBarrett esophagus (BE) with progression to high-grade dysplasia (HGD) or intramucosal carcinoma (IMC) presents a management challenge in patients unfit for surgery. Endoscopic eradication therapies, including radiofrequency ablation (RFA), endoscopic mucosal resection (EMR), and cryotherapy, offer minimally invasive alternatives. This report describes a decade-long course of recurrent HGD and IMC managed entirely through endoscopic interventions in a patient with severe chronic obstructive pulmonary disease, emphasizing the value of personalized and sequential therapeutic strategies. A 71-year-old man with BE and severe chronic obstructive pulmonary disease underwent 18 endoscopic interventions over 10 years, including 5 EMRs, 6 RFAs, and 7 cryotherapy sessions. Despite repeated RFA and EMR, dysplasia recurred multiple times. Cryotherapy initiated after RFA failure achieved complete eradication of dysplasia, intestinal metaplasia, and carcinoma in situ. The patient maintained remission for more than 3 years without recurrence. This case highlights the feasibility of long-term endoscopic management of recurrent HGD and IMC in nonsurgical candidates. INTRODUCTION Barrett esophagus (BE) represents a metaplastic transformation of the distal esophageal epithelium, predisposing to dysplasia and esophageal adenocarcinoma. Progression from intestinal metaplasia (IM) to low-grade dysplasia, high-grade dysplasia (HGD), and eventually intramucosal carcinoma (IMC) is a well-recognized sequence. Although esophagectomy is the definitive treatment for invasive carcinoma, its morbidity and mortality limit its use in patients with advanced cardiopulmonary disease. In such cases, endoscopic eradication therapy (EET) provides a minimally invasive, organ-preserving alternative. EET techniques—including radiofrequency ablation (RFA), endoscopic mucosal resection (EMR), and cryotherapy—have demonstrated high rates of eradication of dysplasia (CE-D) and eradication of intestinal metaplasia (CE-IM). However, recurrence and treatment failure can occur, necessitating iterative or multimodal approaches. This report describes a decade-long management course of recurrent HGD and IMC in an inoperable patient with severe chronic obstructive pulmonary disease (COPD). Through careful use of RFA, EMR, and cryotherapy, long-term remission was achieved, illustrating the critical role of personalized, stepwise endoscopic management in complex cases. CASE REPORT A 71-year-old man with a history of BE and severe oxygen-dependent COPD presented in December 2013 after biopsy-confirmed HGD. Initial endoscopic ultrasound identified mucosal nodularity at 38–40 cm, leading to EMR and RFA sessions between March and December 2015. Nodular Barrett lesions were treated with EMR, while flat residual disease was managed with RFA or cryotherapy rather than repeat EMR or ESD (Figure 1). Number of interventions each year from 2015 to 2024 showing decreased use of RFA and EMR and increased reliance on cryotherapy. EMR, endoscopic mucosal resection; RFA, radiofrequency ablation. Despite 6 RFA sessions in 2015, HGD and IM persisted. Regular surveillance was hindered by frequent COPD exacerbations and atrial fibrillation requiring anticoagulation. In April 2017, surveillance endoscopy revealed recurrent Barrett mucosa with HGD, prompting additional RFA and EMR sessions. However, by late 2017, repeat biopsies still demonstrated noneradicated metaplastic tissue. Given the failure to achieve CE-D after 6 RFA sessions, cryotherapy was introduced as a salvage modality in 2018 (Figure 2). (A) Esophagogastroduodenoscopy from April 2020 demonstrating Barrett mucosa in the distal esophagus. (B) Corresponding narrow-band imaging view of the same area showing mucosal irregularity. Histopathology confirmed high-grade glandular dysplasia. Cryotherapy was performed using nitrous oxide–based C2 CryoBalloon focal ablation system, which delivers circumferential (360°) ablation through a balloon-mounted diffuser without the need for a spray catheter. Each application was delivered for approximately 10 seconds. Sessions ranged from 2 to 9 applications depending on disease extent, with 2–3-month intervals for mucosal healing. Between 2018 and 2023, the patient underwent 7 cryotherapy sessions. After the initial two, there was a visible reduction in Barrett mucosal area, with biopsy-proven partial regression of dysplasia. By the fifth session, all visible Barrett mucosa had resolved, and histopathology demonstrated CE-D and CE-IM. The final 3 sessions were performed for maintenance. The most recent follow-up biopsy in December 2023 confirmed persistent absence of dysplasia or metaplasia (Figure 3). (A) Distal esophageal nodular lesion (1 × 1 cm) in dysplastic Barrett mucosa. (B) Post–en bloc endoscopic mucosal resection defect demonstrating complete resection. Throughout treatment, the patient remained clinically stable, with no procedural complications such as perforation or bleeding. The patient remained compliant with high-dose proton pump inhibitor therapy with well-controlled reflux. Obesity and smoking were additional risk factors, and lifestyle modification was reinforced. The recurrent COPD exacerbations were managed concurrently with pulmonology, emphasizing the multidisciplinary nature of his care. DISCUSSION This case underscores the long-term feasibility and efficacy of sequential endoscopic management for recurrent HGD and IMC in high-risk patients. For this patient, RFA initially failed to achieve durable eradication, consistent with data showing 10%–20% recurrence rates following RFA alone.1 Cryotherapy, which uses rapid freeze-thaw cycles to induce cellular necrosis, provided deeper ablation of residual dysplastic tissue and proved successful as salvage therapy.2 The literature supports this approach: Sengupta et al reported that salvage cryotherapy achieved CE-D in 76% and CE-IM in 46% of patients who failed prior RFA. Similarly, meta-analysis by Visrodia et al. found cryotherapy safe and effective, even in patients with comorbidities precluding surgery.3 The increased use of cryotherapy reflected both prior RFA failure and the preference for ablation of flat residual Barrett epithelium, while EMR remains best suited for visible lesions. This is consistent with current guidance favoring focal EMR plus ablation over stepwise EMR.4 RFA targets superficial mucosa, whereas cryotherapy penetrates deeper layers via ice crystal formation, potentially eradicating resistant cells.5 This depth of effect likely contributed to the durable CE-D and CE-IM observed in this case. Furthermore, cryotherapy's hemostatic properties and lack of contact make it especially advantageous for patients on anticoagulation, such as our patient with atrial fibrillation. A significant challenge in long-term EET is recurrence. Studies show that recurrence of IM or HGD after initial CE-IM occurs in 5%–15% of patients over 3–5 years. Continuous surveillance and readiness to reapply therapy are crucial to achieving sustained remission. Posteradication surveillance should be individualized according to the worst pretreatment histology rather than the most recent biopsy alone. For patients with prior HGD or IMC who achieve CE-IM, current American College of Gastroenterology and American Gastroenterological Association guidance supports surveillance at 3, 6, and 12 months and then annually thereafter. In our patient, this histology-driven approach was particularly important given recurrent HGD/IMC over time.4 In this case, persistent follow-up despite frequent COPD hospitalizations allowed timely retreatment before progression to invasive carcinoma. Argon Plasma Coagulation may be considered for treatment of small residual Barrett islands, although it is typically used as an adjunctive “touch-up” modality rather than a first-line eradication strategy.6 The choice of endoscopic technique must also consider comorbidities and patient tolerance. Our patient's severe COPD precluded esophagectomy, aligning with evidence that EET yields comparable survival with far lower morbidity. Ganapathy-Prasad et al demonstrated equivalent 5-year survival between EET and surgical cohorts, reinforcing the paradigm shift toward endoscopic management even for early-stage carcinoma.7 This case also highlights the necessity of multidisciplinary coordination. Close collaboration between gastroenterology, pulmonology, and pathology ensured appropriate timing, risk mitigation, and accurate histologic interpretation. Such integrated care models are key to managing chronic, recurrent BE-related neoplasia over extended time frames. Endoscopic therapy offers an effective, minimally invasive approach for managing recurrent HGD and IMC in patients who are not surgical candidates. This case demonstrates that iterative, patient-tailored endoscopic therapy—progressing from RFA and EMR to cryotherapy—can achieve durable remission over a decade of follow-up. Failure of RFA should prompt consideration of cryotherapy, particularly in high-risk patients with cardiopulmonary comorbidities or anticoagulation needs. Long-term success depends on vigilant surveillance, multidisciplinary collaboration, and flexibility in therapeutic strategy. Further reporting will strengthen evidence guiding optimal treatment sequencing in Barrett-associated neoplasia. DISCLOSURES Author contributions: M. Alharami: Assisted with gathering clinical information and organizing the case details. Contributed to literature review and helped revise the manuscript. A. Anbar: Assisted with data collection and chart review. Participated in drafting selected sections and reviewing the manuscript. Z. Sulieman: Contributed to the literature search and background review. Assisted in organizing case chronology and manuscript editing. H. Hemaidan: Helped with data organization, preparing case materials, and arranging figures obtained from the clinical team. Assisted with reference formatting and background research. M. Alali: Assisted with manuscript writing and organization. Helped prepare the final version of the manuscript for submission. M. Alharami is the article guarantor. Financial disclosure: None to report. Informed consent was obtained for this case report.